Drug Trial Radar · NCT07905183
A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Dec 31, 2026
Primary completion
Dec 31, 2028
Study completion Jul 2033
Sponsor
- Lead sponsor
- Enliven TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.
Conditions
- Chronic Myeloid Leukemia (CML)
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
- Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML
Interventions
ELVN-001Drug
ELVN-001 orally daily
TKIDrug
TKI orally daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKITime frame: 24 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Winship Cancer Institute
Atlanta, Georgia · Recruiting
Investigative Clinical Research of Indiana, LLC
Indianapolis, Indiana · Recruiting
Atlantic Health System
Morristown, New Jersey · Recruiting
Community Center Trials of Utah
Ogden, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.